METHODS: 309 CRS patients were recruited. All patients rated their burden of 5 symptoms (nasal blockage, rhinorrhea/postnasal drip, facial pain/pressure, smell loss, sleep disturbance or fatigue) using the binary EPOS descriptive symptom scales and a VAS (on a scale of 0 to 10). In addition, participants completed a 22-item Sinonasal Outcome Test (SNOT-22) and rated their overall CRS disease control as \"controlled\", \"partly controlled\" or \"uncontrolled\" Results: Symptom burdens measured by VAS, binary descriptive EPOS scale and SNOT-22 were associated with worsening CRS disease control reported by participants. Each symptom had a distinct VAS score cut-off that strongly predicted the uncontrolled option on the corresponding binary descriptive EPOS symptom scale. However, the predictive ability of VAS for rhinorrhea/ postnasal drip was disparately worse than the other 4 symptoms. When considering all symptom data simultaneously, a VAS score higher than 3.5 strongly predicted the uncontrolled option on the corresponding binary descriptive EPOS symptom scale for all 5 symptoms.
CONCLUSIONS: A VAS symptom score of higher than 3.5 translates to the uncontrolled option in the binary, descriptive symptom scale of the EPOS control criteria. The rhinorrhea/postnasal drip descriptive symptom scale translates disparately worse to VAS scores and may be considered for revision in future criteria.
方法:招募了309名CRS患者。所有患者都评估了他们的5种症状负担(鼻塞,鼻漏/鼻后滴漏,面部疼痛/压力,气味损失,睡眠障碍或疲劳)使用二元EPOS描述性症状量表和VAS(0至10的量表)。此外,参与者完成了22项鼻窦结果测试(SNOT-22),并将他们的CRS疾病总体控制评分为“控制”,\"部分受控\"或\"不受控\"。
结果:通过VAS测量的症状负担,二元描述性EPOS量表和SNOT-22与参与者报告的CRS疾病控制恶化相关.每种症状都有不同的VAS评分截止值,可以在相应的二元描述性EPOS症状量表上强烈预测不受控制的选择。然而,VAS对鼻漏/鼻后滴漏的预测能力远不如其他4种症状。当同时考虑所有症状数据时,VAS评分>3.5在所有5种症状的相应二元描述性EPOS症状量表上强烈预测了不受控制的选择。
结论:>3.5的VAS症状评分转化为二元模型中的不受控制选项,EPOS控制标准的描述性症状量表。鼻漏/鼻后滴注描述性症状量表对VAS评分的翻译程度不同,可能会考虑在将来的标准中进行修订。